ERBB2 and breast cancer: The power calculation for the second set also indicated that the validation samples had a low power of 20−35% to identify a true association between risk of HER2+ subtype breast cancer and rs4919510:C>G if we assumed the relative risk of G-allele at 1.5–1.8.